DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Study Overview

This research study is studying whether participants and their doctors are willing to determine post-surgery treatment on the basis of response to pre-surgery treatment, and studying blood and tissue collected from participants treated with a combination of drugs as a treatment for breast cancer.

The names study drugs involved in this study are:

  • Paclitaxel (also called Taxol)
  • Trastuzumab (also called Herceptin)
  • Pertuzumab (also called Perjeta)

Study Description

DAPHNe: De-escalation to adjuvant antibodies post-pCR to neoadjuvant THP (paclitaxel/trastuzumab/pertuzumab)-a pilot study in HER2-positive breast cancer

  • ClinicalTrials.gov Identifier: NCT03716180
  • Protocol Number: 18-394
  • Principal Investigator: Neelam Desai

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000